𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The rationale for the ERSPC trial: will it improve the knowledge base on prostate cancer screening?

✍ Scribed by A. Auvinen; J. Hugosson


Book ID
109050829
Publisher
John Wiley and Sons
Year
2003
Tongue
English
Weight
56 KB
Volume
92
Category
Article
ISSN
1464-4096

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


The effect of study arm on prostate canc
✍ Tineke Wolters; Monique J. Roobol; Ewout W. Steyerberg; Roderick C.N. van den Be πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 French βš– 138 KB πŸ‘ 1 views

## Abstract Prostate cancer (PC) mortality is the most valid end‐point in screening trials, but could be influenced by the choice of initial treatment if treatment has an effect on mortality. In this study, PC treatment was compared between the screening and control arms in a screening trial. Data

Prostate cancer mortality reduction by s
✍ Harry J. de Koning; Michael K. Liem; Caroline A. Baan; Rob Boer; Fritz H. SchrΓΆd πŸ“‚ Article πŸ“… 2001 πŸ› John Wiley and Sons 🌐 French βš– 97 KB πŸ‘ 2 views

## Abstract From 1992–2001, 7 countries in Europe gradually recruited men for the European Randomised Screening for Prostate Cancer (ERSPC) trial. Centres recruit different age groups and have different designs for recruiting and countries have different underlying risks for prostate cancer. Recrui

Large-scale randomized prostate cancer s
✍ Harry J. de Koning; Anssi Auvinen; Antonio Berenguer Sanchez; Fernando Calais da πŸ“‚ Article πŸ“… 2001 πŸ› John Wiley and Sons 🌐 French βš– 79 KB πŸ‘ 2 views

## Abstract Two large‐scale randomized screening trials, the Prostate, Lung, Colorectal and Ovary (PLCO) cancer trial in the USA and the European Randomized Screening for Prostate Cancer (ERSPC) trial in Europe are currently under way, aimed at assessing whether screening reduces prostate cancer mo